Transforming the future of back pain treatment
SpinaFX is a medical treatment solution company providing rapid and sustained relief to patients with back pain due to contained lumbar herniated discs, using innovative, minimally invasive image-guided therapy.
Back Pain is the #1 cause of disability in the world 1 and the most expensive health condition treated2 .
Filling a Therapeutic Gap for Contained Herniated Disc-Related Back and Leg Pain

Lumbar disc herniation affects between 5 and 20 adults per 1,000 annually.3 For many of these patients, there is a gap in treatment options for contained lumbar disc herniation that would fall between conservative care and surgery. Some find conservative treatment options address their symptoms but fail to treat the root cause of pain. For others, surgery could be an undesired option.
1.NIH Low Back Pain Fact Sheet https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Low-Back-Pain-Fact-Sheet
2.Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA. 2020;323(9):863–884. doi:10.1001/jama.2020.0734
3.Al Qaraghli MI, De Jesus O. Lumbar Disc Herniation. [Updated 2021 Aug 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560878/
SpinaFX
Pioneering minimally invasive, image-guided treatments

A New Treatment Option for Radiculopathy
Our flagship treatment solution aims to relieve back and leg pain caused by a contained herniated disc through the intravertebral injection of a mixture of oxygen and ozone gas.1 This technology is not currently available for promotion or sale.
Promising research shows there is a potential for oxygen-ozone injections to help treat radiculopathy caused by a contained herniated lumbar disc. In fact, a study of 283 patients showed intradiscal ozone injections are associated with a statistically significant volume reduction of the herniated lumbar disc2. An average disc volume reduction was seen in 96.1% of treated disks six months after treatment2* Animal studies and mathematical modeling have shown a 6% nucleus pulposus volume reduction can lead to a 9.84% reduction in pressure, relieving nerve root compression and herniated disc-related pain.3
* Average disc volume reduction (mean 7.7+/-5.45%; range, 0.29%-22.31%). P < 0.0001.
- Triojection™ is not currently available for promotion or sale in North America, the EU, or the U.K. Triojection was previously awarded CE Mark under MDD and is undertaking re-registration under MDR. Contact SpinaFX for further information regarding anticipated commercial availability in your region.
- Lehnert T et al 2012, Lumbar Disk Volume before and after Ozone–Oxygen Injection, pubmed.ncbi.nlm.nih.gov/22999458/
- Murphy et al, 2016, Percutaneous Treatment of Herniated Lumbar. Discs with Ozone: Investigation of the Mechanisms of Action.pubmed.ncbi.nlm.nih.gov/27363296/
SpinaFX News


SpinaFX Completes its Series B Funding Round

ASSR Las Vegas

RESI San Francisco

MNVC Conference

NASS 2023

Addition to SpinaFX Team
